India is the largest provider of generic medicines in the world with a 20 per cent supply share in terms of volumes. As per data released by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, domestic pharmaceutical market turnover amounted to Rs. 129,015 crore (USD 18.12 billion). This figure increased in the FY 19 with a turnover of USD 19.14 billion.
India enjoys a significant position in the global pharma sector. The country is also the largest producer of vaccine.
The company is an agricultural science firm founded in India. They came to us with the aim of becoming a leading producer of plant-based health products by the means of expansion and commercial optimization.
While the company had the right technology, they lacked the means to make their company a big brand in a highly competitive market. They came to us looking not only for foreign investors, but also the right business partners who would help commercialize their plant-based innovation.
As is first with every project we accept, we thoroughly researched the plan to deduce the foreign direct investment availability. We mapped the entry routes and any complications the project may face in the future. The challenge for us was to guide the entire project through the lengthy process of foreign direct investment without incurring major difficulties.
We connected the company with interested foreign investors, and hereafter, the project commenced.